Overcoming toxicities when combining PI3K inhibitors with other treatments
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of...
Author: VJHemOnc
Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts
iwNHL 2017 highlights: the PDX model
Marek Trneny, MD, from the Charles University, Prague, Czech Republic, discusses highlights from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. The PDX...
Author: VJHemOnc
Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts
CC122: a new IMiD in the treatment of diffuse large B-cell lymphoma
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Van...
Author: VJHemOnc
Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts
CAR-T cell therapy debate: the future of lymphoma treatment?
CAR-T cell therapy is an innovative new strategy that may revolutionize lymphoma treatment. Speaking from the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Graham Collins...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
New lymphoma drug studies show promise
New studies are constantly evolving the field of lymphoma research, with trials continuously striving to find more effective treatments. At the 2017 National Cancer Research Institute (NCRI) Conferenc...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
Revolutionary immunotherapy for lymphoma
Immunotherapy has emerged in recent years as a promising lymphoma treatment, with exciting new drug classes being developed with innovative mechanisms of action. Here, Graham Collins, MA, MBBS, MRCP, ...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
Checkpoint inhibitors in Hodgkin lymphoma
There are two well-known checkpoint inhibitors that have shown efficacy in relapses/refractory Hodgkin lymphoma, nivolumab and pembrolizumab, both PD-1 inhibitors. Here, John Kuruvilla, MD, FRCPC at t...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
Targeting chemokines in lymphoma
Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses targeting chemokines at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancou...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
